CDEK by Data4ThePeople

Sign in Sign up

← All drugs Report issue

jnj-87890387

mAbexperimentalBi-specific

Clinical trial activity

1 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Dec 29, 2023 (NCT06178614)

Timeline

No events for the selected filters.

Indications

Studied for

Neoplasms · Phase 1

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainACTIVATOR
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3BINDING AGENT
ENPP3 binding agent
- Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) ↗

Chemistry & pharmacology

Multi-specific: Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06178614	Phase 1	Dec 29, 2023	—

Showing 1 of 1 trials

Page 1 / 1